Navigation Links
Mindray Announces Third Quarter 2010 Financial Results
Date:11/8/2010

SHENZHEN, China, Nov. 8, 2010 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the third quarter and nine months ended September 30, 2010.Highlights for 2010 Third Quarter and Nine Months

  • Third quarter 2010 net revenues were $168.3 million, an increase of 11.3% over the third quarter of 2009. First nine months net revenues were $493.3 million, an increase of 10.8% year-over-year.
  • Strong international sales of $99.2 million as compared to $84.3 million for the third quarter of 2009, a year-over-year increase of 17.7%.
  • Non-GAAP net income increased 5.8% year-over-year to $39.5 million from $37.4 million in the third quarter of 2009. First nine months non-GAAP net income was $125.6 million, an increase of 18.8% year-over-year.
  • Gross margin in the third quarter of 2010 was 58.8%, compared to 56.6% in the third quarter of 2009 and 58.3% in the second quarter of 2010.
  • Net operating cash generated during the third quarter of 2010 was $27.9 million.
  • The company launched nine new products and several new reagents across its three product lines year to date.

  • "Our results this quarter reflected strong international sales growth, which grew 17.7% year-over year," commented Xu Hang, Mindray's Chairman and Co-Chief Executive Officer. "We are encouraged by the continued growth momentum in both emerging and developed markets. Similar to last quarter, Latin America, the CIS region and the Middle East led growth among all regions while the developed markets again recorded double-digit growth. In China, revenues grew 3.3% year-over-year, not as strong as the year prior largely as a result of continued softening in government spending for medical device purchasing, as well as tier two and below hospitals continuing to lag in self-funded purchases. Tender sales were flat from last quarter. While the long-term prospects of the healthcare sector in China driven by reform remain favorable, the timing associated with medical device purchasing under the plan remains unclear. Non-tender sales grew 1% year-over-year. As we have communicated to investors, we are realigning our sales force and undertaking other strategic initiatives in product development and marketing in order to focus on building out presence in both high-end and low-end market segments, as well as to improve operational efficiency. Mindray continues to focus on innovation and we are pleased to announce the planned openings of three new R&D centers by end of this year."SUMMARY –ThirdQuarter and Nine Months Ended September 30, 2010(in $ millions, except per-share data)

    Three Months Ended

    Nine Months EndedSeptember 30

    September 302010

    2009

    % chg

    2010

    2009

    % chgNet Revenues

    168.3

    151.1

    11.3%

    493.3

    445.3

    10.8%Revenues generated in China

    69.1

    66.8

    3.3%

    203.6

    205.1

    -0.7%Revenues generated outside China

    99.2

    84.3

    17.7%

    289.7

    240.2

    20.6%Gross Profit

    99.0

    85.5

    15.7%

    285.7

    251.8

    13.4%Non-GAAP Gross Profit

    100.2

    87.2

    14.9%

    289.8

    256.8

    12.8%Operating Income

    38.7

    34.2

    13.2%

    118.2

    102.6

    15.2%Non-GAAP Operating Income

    42.4

    40.0

    5.9%

    129.5

    118.6

    9.2%EBITDA

    45.8

    60.1

    -23.8%

    138.8

    142.3

    -2.5%Net Income

    35.9

    43.4

    -17.2%

    114.4

    101.8

    12.4%Non-GAAP Net Income

    39.5

    37.4

    5.8%

    125.6

    105.7

    18.8%Diluted EPS

    0.30

    0.38

    -20.4%

    0.97

    0.90

    7.9%Non-GAAP Diluted EPS

    0.34

    0.33

    1.7%

    1.07

    0.94

    14.0%RevenuesMindray reported net revenues of $168.3 million for the third quarter of 2010, an 11.3% increase from $151.1 million in the third quarter of 2009. Net revenues generated in China in the third quarter of 2010 increased 3.3% to $69.1 million from $66.8 million in the third quarter of 2009, while net revenues generated in international markets in the third quarter of 2010 increased 17.7% to $99.2 million from $84.3 million in the third quarter of 2009.

    Performance by SegmentPatient Monitoring & Life Support Products: Patient monitoring & life support products segment revenues increased 7.2% to $72.6 million from $67.7 million in the third quarter of 2009. The patient monitoring & life support products segment contributed 43.1% to total net revenues in the third quarter of 2010.

    In-Vitro Diagnostic Products: In-vitro diagnostic products segment revenues increased 15.5% to $43.1 million from $37.3 million in the third quarter of 2009. The in-vitro diagnostic products segment contributed 25.6% to total net revenues in the third quarter of 2010.

    Medical Imaging Systems: Medical imaging systems segment revenues increased 17.5% to $42.7 million from $36.4 million in the third quarter of 2009. The medical imaging systems segment contributed 25.4% to total net revenues in the third quarter of 2010.

    Others: Other revenues, which are primarily comprised of service fees charged for post warranty period repair services, increased 1.4% to $9.9 million from $9.7 million in the third quarter of 2009. Other revenues contributed 5.9% to total net revenues in the third quarter of 2010.

    The segment revenue amounts discussed above include shipping and handling fees charged to customers.

    Gross MarginsThird quarter 2010 gross profit was $99.0 million, a 15.7% increase from $85.5 million in the third quarter of 2009. Third quarter 2010 non-GAAP gross profit was $100.2 million, a 14.9% increase from $87.2 million in the third quarter of 2009. Third quarter 2010 gross margin was 58.8% compared to 56.6% in the third quarter of 2009 and 58.3% in the second quarter of 2010. Non-GAAP gross margin was 59.5% in the third quarter of 2010 compared to 57.7% in the third quarter of 2009 and 59.0% in the second quarter of 2010.

    Operating ExpensesSelling expenses for the third quarter of 2010 were $30.2 million, or 18.0% of total net revenues, compared to 16.4% in the third quarter of 2009 and 15.2% in the second quarter of 2010. Non-GAAP selling expenses for the third quarter of 2010 were $29.0 million, or 17.2% of total net revenues, compared to 15.4% in the third quarter of 2009 and 14.5% in the second quarter of 2010.

    General and administrative expenses for the third quarter of 2010 were $15.2 million, or 9.0% of total net revenues, compared to 7.5% in the third quarter of 2009 and 8.6% in the second quarter of 2010. Non-GAAP general and administrative expenses for the third quarter of 2010 were $14.7 million, or 8.8% of the total net revenues, compared to 6.9% in the third quarter of 2009 and 8.4% in the second quarter of 2010.

    Research and development expenses for the third quarter of 2010 were $14.8 million, or 8.8% of total net revenues, compared to 9.4% in the third quarter of 2009 and 8.0% in the second quarter of 2010. Non-GAAP research and development expenses for the third quarter of 2010 were $14.0 million, or 8.3% of total net revenues, compared to 8.8% in the third quarter of 2009 and 7.6% in the second quarter of 2010.

    Total share-based compensation expenses, which were allocated to cost of revenues and related operating expenses, were $1.9 million in the third quarter of 2010 compared to $1.8 million in the second quarter of 2010 and $2.6 million in the third quarter of 2009.

    Operating income was $38.7 million in the third quarter of 2010, a 13.2% increase from $34.2 million in the third quarter of 2009. Non-GAAP operating income in the third quarter of 2010 was $42.4 million, a 5.9% increase from $40.0 million in the third quarter of 2009. Operating margin was 23.0% in the third quarter of 2010 compared to 22.6% in the third quarter of 2009 and 26.5% in the second quarter of 2010. Non-GAAP operating margin was 25.2% in the third quarter of 2010 compared to 26.5% in the third quarter of 2009 and 28.6% in the second quarter of 2010.

    Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA")Third quarter 2010 EBITDA declined 23.8% year-over-year to $45.8 million from $60.1 million in the third quarter of 2009 and decreased 15.5% from $54.2 million in the second quarter of 2010. The year-over-year decline was primarily due to a one-time income in the third quarter of 2009 of $14.0 million from Beckman Coulter, based on the termination of a joint development and OEM project.

    Net IncomeNet income decreased 17.2% year-over-year to $35.9 million from $43.4 million in the third quarter of 2009. Non-GAAP net income increased 5.8% year-over-year to $39.5 million from $37.4 million in the third quarter of 2009. Net margin was 21.4% in the third quarter of 2010 compared to 28.7% in the third quarter of 2009 and 23.6% in the second quarter of 2010. Non-GAAP net margin was 23.5% in the third quarter of 2010 compared to 24.7% in the third quarter of 2009 and 25.6% in the second quarter of 2010. Third quarter 2010 income tax expense was $6.4 million representing an effective tax rate of 15.1%.

    Third quarter 2010 basic and diluted earnings per share were $0.31 and $0.30, respectively, compared to $0.40 and $0.38 in the third quarter of 2009. Basic and diluted non-GAAP earnings per share were $0.35 and $0.34, respectively, compared to $0.34 and $0.33 in the third quarter of 2009. Shares used in the computation of diluted earnings per share for the third quarter 2010 and third quarter 2009 were 117.9 million and 113.4 million, respectively.

    Other Select DataAverage accounts receivable days outstanding were 68 days in the third quarter of 2010 compared to 58 days in the second quarter of 2010. Average inventory days were 116 days in the third quarter of 2010 compared to 93 days in the second quarter of 2010. Average accounts payable days outstanding were 66 days in the third quarter of 2010 compared to 59 days in the second quarter of 2010. Mindray calculates the above working capital days using the average of beginning and ending balances of the quarter.

    As of September 30, 2010, the company had total $381.9 million in cash and cash equivalents, and short-term investments as compared to $370.2 million as of June 30, 2010. Net cash generated from operating activities and net cash outflow for capital expenditures during the quarter were $27.9 million and $17.0 million, respectively.

    As of September 30, 2010, the company had 6,236 employees.

    Nine Months Ended September 30, 2010 ResultsMindray reported net revenues of $493.3 million for the first nine months of 2010, representing a 10.8% increase from $445.3 million in the same period in 2009.

  • Net revenues generated in China in the first nine months of 2010 decreased 0.7% to $203.6 million from $205.1 million in the same period in 2009.
  • Net revenues generated in international markets in the first nine months of 2010 increased 20.6% to $289.7 million from $240.2 million in the first nine months of 2009.

  • First nine months of 2010 EBITDA decreased 2.5% year-over-year to $138.8 million from $142.3 million in the first nine months of 2009.

    First nine months of 2010 net income increased 12.4% year-over-year to $114.4 million from $101.8 million in the first nine months of 2009. First nine months of 2010 non-GAAP net income increased 18.8% year-over-year to $125.6 million from $105.7 million in the first nine months of 2009.

    First nine months of 2010 diluted earnings per share increased 7.9% year-over-year to $0.97 from $0.90 in the first nine months of 2009. First nine months of 2010 non-GAAP diluted earnings per share increased 14.0% to $1.07 from $0.94 in the first nine months of 2009.

    Business Outlook for Full Year 2010The company maintains its full year guidance and expects its full year 2010 net revenues to be $700 million.

    The company continues to expect its full year 2010 non-GAAP net income to grow 10% over its non-GAAP net income for full year 2009, excluding the $8.6 million corporate income tax reduction recognized in the first quarter of 2010. This guidance assumes a corporate income tax rate of 15% applicable to the Shenzhen subsidiary.

    The company expects its capital expenditure for 2010 to remain in the range of $60 million to $70 million.

    The company's practice is to provide guidance on a full year basis only. This forecast reflects Mindray's current and preliminary views, which are subject to change.

    "We are maintaining our guidance at this time. While we are pleased with our performance in the international markets and expect solid international sales trends to continue, we are also taking aggressive measures in the areas of product development, sales force organization, branding and marketing in order to restore growth in non-tender sales in China," commented Li Xiting, Mindray's President and Co-Chief Executive Officer. "We remain firm in our belief that China's healthcare sector continues to be a major segment that attracts heavy investment from both the Chinese government and private capital, which provides promising long-term development prospects for companies like Mindray. We are confident that the implementation of our strategic initiatives in China, our commitment to invest in international markets, as well as our R&D effort, will continue to help fuel Mindray's future growth."

    Conference Call InformationMindray's management will hold an earnings conference call at 8:00 AM on November 9, 2010 U.S. Eastern Time (9:00 PM on November 9, 2010 Beijing/Hong Kong Time).

    Dial-in details for the earnings conference call are as follows:

    Hong Kong:

    +852-3002-1672U.S. Toll Free:

    +1-866-362-5158International:

    +1-617-597-5397Pass code for all regions:

    MindrayA replay of the conference call may be accessed by phone at the following numbers until November 23, 2010.

    U.S. Toll Free:

    +1-888-286-8010International:

    +1-617-801-6888Pass code:

    1158 6347Additionally, a live and archived webcast of this conference call will be available on the Investor Relations section of Mindray's website at http://ir.mindray.com.

    Use of Non-GAAP Financial MeasuresMindray provides gross profit, R&D expenses, selling expenses, general and administrative expenses, operating income, net income and earnings per share on a non-GAAP basis that excludes share-based compensation expense, acquired intangible assets amortization expense, realignment costs – post acquisition, and other income from onetime early termination of contract, all net of related tax impact, as well as EBITDA to enable investors to better assess the company's operating performance. The non-GAAP measures described by the company are reconciled to the corresponding GAAP measure in the exhibit below titled "Reconciliations of non-GAAP results of operations measures to the nearest comparable GAAP measures".

    The company has reported for the third quarter of 2010 and provided guidance for full year 2010 earnings per share on a non-GAAP basis. Each of the terms as used by the company is defined as follows:

  • Non-GAAP gross profit represents gross profit reported in accordance with GAAP, adjusted for the effects of share-based compensation and amortization of acquired intangible assets.
  • Non-GAAP operating income represents operating income reported in accordance with GAAP, adjusted for the effects of share-based compensation, realignment cost – post acquisition and amortization of acquired intangible assets.
  • Non-GAAP net income represents net income reported in accordance with GAAP, adjusted for the effects of share-based compensation, realignment cost – post acquisition, amortization of acquired intangible assets and other income from onetime early termination of contract, all net of related tax impact.
  • Non-GAAP earnings per share represents non-GAAP net income divided by the number of shares used in computing basic and diluted earnings per share in accordance with GAAP, and excludes the impact of the declared dividends for the basic calculation.
  • EBITDA represents net income reported in accordance with GAAP, adjusted for the effect of interest income and expenses, provision of income taxes, depreciation and amortization.

  • The company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The company notes that these measures may not be calculated on the same basis of similar measures used by other companies. Readers are cautioned not to view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of GAAP results with non-GAAP results for the three months and nine months period ended September 30, 2009 and 2010, respectively, in the attached financial information.

    Cautionary Note Regarding Forward-Looking StatementsThis press release contains "forward-looking statements," including those related to the company's selected unaudited 2010 financial results, the company's business outlook for the fiscal year 2010, including with respect to net revenues, non-GAAP net income, capital expenditure, anticipated growth or recovery in particular geographic or product markets including emerging markets and high-end product and developed markets, the impact of anticipated healthcare reform or government expenditures, the level of investment in healthcare from government and private sources, the company's ability to benefit from planned company investments and new strategic initiatives in product development, sales force organization, realignment of our international sales networks, branding and marketing, or to derive anticipated operation synergies, to improve cost structures and operational efficiencies to benefit from government tender sales in China, the growth of non-tender sales in China, and hospital self-funded sales, and our expectation that China and international sales will remain parallel growth drivers for the company. These statements are not historical facts but instead represent only our belief regarding future events or circumstances, many of which, by their nature, are inherently uncertain and outside of our control. It is possible that our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including but not limited to: the expected growth of the medical device market in China and internationally; relevant government policies and regulations relating to the medical device industry; market acceptance of our products; our expectations regarding demand for our products; our ability to expand our production, our sales and distribution network and other aspects of our operations; our ability to stay abreast of market trends and technological advances; our ability to effectively protect our intellectual property rights and not infringe on the intellectual property rights of others; competition in the medical device industry in China and internationally; and general economic and business conditions in the countries in which we operate. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 7 of our annual report on Form 20-F, filed on May 25, 2010. Our results of operations for the third quarter of 2010 are not necessarily indicative of our operating results for any future periods. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this release.

    All references to "shares" are to our ordinary shares, which are divided into two classes, Class A and Class B. Each of our American Depositary Shares, which trade on the New York Stock Exchange, represents one Class A ordinary share.

    About MindrayWe are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain our global operational headquarters in Shenzhen, China, and multiple sales offices in major domestic and international markets. From our main manufacturing and engineering base in China and through our worldwide distribution network, we supply internationally a broad range of products across three primary business segments, comprised of patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems. For more information, please visit http://ir.mindray.com.

    For investor and media inquiries please contact:In the U.S:Hoki LukWestern Bridge, LLCTel:   +1-646-808-9150Email: hoki.luk@westernbridgegroup.comIn China: May LiMindray Medical International LimitedTel: + 86 755 2658 2518Email: may.li@mindray.comExhibit 1MINDRAY MEDICAL INTERNATIONAL LIMITEDCONDENSED CONSOLIDATED BALANCE SHEETS(Dollars in thousands)As of December 31, 2009

    As of September 30, 2010US$

    US$ (Note 2)

    (unaudited) ASSETSCurrent assets:Cash and cash equivalents

    204,228

    164,715Restricted cash and restricted investments (Note 1)

    102,257

    -Short-term investments

    -

    217,180Accounts receivable, net

    113,340

    129,474Inventories

    64,518

    93,515Value added tax receivables

    8,519

    12,350Other receivables

    8,999

    7,372Prepayments and deposits

    7,466

    8,679Deferred tax assets

    2,338

    2,942Total current assets

    511,665

    636,227Restricted investment (Note 1)

    66,000

    -Other assets

    1,585

    2,930Advances for purchase of plant and equipment

    28,395

    16,155Property, plant and equipment, net

    153,726

    187,488Land use rights, net

    25,776

    45,267Intangible assets, net

    64,065

    63,813Goodwill

    115,053

    115,150Total assets

    966,265

    1,067,030LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Short-term bank loans (Note 1)

    103,128

    -Notes payable

    5,647

    6,179Accounts payable

    35,752

    39,187Advances from customers

    10,081

    6,718Salaries payables

    19,877

    20,588Other payables

    56,592

    64,893Income taxes payable

    16,199

    10,970Deferred tax liabilities

    1,499

    -Other taxes payable

    5,863

    1,279Total current liabilities

    254,638

    149,814Bank loans- long term (Note 1)

    66,000

    -Other long-term payables

    1,342

    1,040Deferred tax liabilities, net

    3,734

    6,10171,076

    7,141Shareholders' equity:Ordinary shares

    14

    15Additional paid-in capital

    298,408

    463,806Retained earnings

    301,476

    393,094Accumulated other comprehensive income

    40,651

    53,158Total shareholders' equity

    640,549

    910,073Non- controlling interest

    2

    2Total equity

    640,551

    910,075Total liabilities and shareholders' equity

    966,265

    1,067,030(1) Restricted as the security package required for the bank loans as of December 31, 2009. Use of such funds are permitted provided that the proportionate amount of debt must be retired concurrently. As of September 30, 2010, the bank loans were fully repaid.

    (2) Financial information is extracted from the audited financial statements included in the company's fiscal 2009 Form 20-F.Exhibit 2MINDRAY MEDICAL INTERNATIONAL LIMITEDCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Dollars in thousands, except for share and per share data)Three months ended September 30,

    Nine months ended September 30,2009

    2010

    2009

    2010US$

    US$

    US$

    US$ (unaudited)

    (unaudited)

    (unaudited)

    (unaudited)Net revenues-PRC

    66,809

    69,037

    205,123

    203,606- International

    84,319

    99,237

    240,230

    289,728Net revenues

    151,128

    168,274

    445,353

    493,334Cost of revenues (note 2)

    (65,607)

    (69,287)

    (193,536)

    (207,660)Gross profit

    85,521

    98,987

    251,817

    285,674Selling expenses (note 2)

    (24,805)

    (30,215)

    (73,004)

    (81,066)General and administrative expenses (note 2)

    (11,291)

    (15,221)

    (31,524)

    (42,864)Research and development expenses (note 2)

    (14,168)

    (14,802)

    (43,636)

    (43,553)Realignment costs — post acquisition

    (1,030)

    -

    (1,030)

    -Operating income

    34,227

    38,749

    102,623

    118,191Other income , net

    18,719

    60

    19,071

    137Interest income

    1,776

    4,157

    4,717

    8,670Interest expense

    (1,091)

    (620)

    (3,881)

    (2,463)Income before income taxes and non-controlling interests

    53,631

    42,346

    122,530

    124,535Provision for income taxes

    (10,209)

    (6,408)

    (20,753)

    (10,118)Net Income

    43,422

    35,938

    101,777

    114,417Less: Net income attributable to non-controlling interests

    -

    -

    -

    -Net Income attributable to the Company

    43,422

    35,938

    101,777

    114,417Basic earnings per share

    0.40

    0.31

    0.94

    1.01Diluted earnings per share

    0.38

    0.30

    0.90

    0.97Shares used in the computation of:Basic earnings per share

    108,845,481

    114,489,052

    108,337,457

    113,351,832Diluted earnings per share

    113,374,202

    117,884,600

    112,671,743

    117,396,900(2) Share-based compensation charges incurred during the period related to:Cost of revenues

    124

    61

    373

    246Selling expenses

    878

    570

    2,858

    1,860General and administrative expenses

    832

    486

    2,574

    1,256Research and development expenses

    802

    771

    2,444

    2,220Exhibit 3MINDRAY MEDICAL INTERNATIONAL LIMITEDRECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES(Dollars in thousands, except for share and per share data)Three months ended September 30,

    Nine months ended September 30,2009

    2010

    2009

    2010US$

    US$

    US$

    US$(unaudited)

    (unaudited)

    (unaudited)

    (unaudited)Non-GAAP net income37,376

    39,538

    105,726

    125,570Non-GAAP net margin

    24.7%

    23.5%

    23.7%

    25.5%Amortization of acquired intangible assets

    (2,135)

    (1,745)

    (6,484)

    (5,745)Deferred tax impact related to acquired intangible assets

    90

    33

    288

    174Realignment costs — post acquisition

    (1,030)

    -

    (1,261)

    -Income from early termination of contract

    11,757

    -

    11,757

    -Share-based compensation

    (2,636)

    (1,888)

    (8,249)

    (5,582)GAAP net income

    43,422

    35,938

    101,777

    114,417GAAP net margin

    28.7%

    21.4%

    22.9%

    23.2%Non-GAAP income per share - basic

    0.34

    0.35

    0.98

    1.11Non-GAAP income per share - diluted

    0.33

    0.34

    0.94

    1.07GAAP income per share - basic

    0.40

    0.31

    0.94

    1.01GAAP income per share - diluted

    0.38

    0.30

    0.90

    0.97 Shares used in computation of: Basic earnings per share

    108,845,481

    114,489,052

    108,337,457

    113,351,832 Diluted earnings per share

    113,374,202

    117,884,600

    112,671,743

    117,396,900Non-GAAP operating income40,028

    42,382

    118,617

    129,518Non-GAAP operating margin

    26.5%

    25.2%

    26.6%

    26.3%Amortization of acquired intangible assets

    (2,135)

    (1,745)

    (6,484)

    (5,745)Realignment costs — post acquisition

    (1,030)

    -

    (1,261)

    -Share-based compensation

    (2,636)

    (1,888)

    (8,249)

    (5,582)GAAP operating income

    34,227

    38,749

    102,623

    118,191GAAP operating margin

    22.6%

    23.0%

    23.0%

    24.0%Non-GAAP gross profit87,153

    100,174

    256,806

    289,805Non-GAAP gross margin

    57.7%

    59.5%

    57.7%

    58.7%Amortization of acquired intangible assets

    (1,508)

    (1,126)

    (4,616)

    (3,885)Share-based compensation

    (124)

    (61)

    (373)

    (246)GAAP gross profit

    85,521

    98,987

    251,817

    285,674GAAP gross margin

    56.6%

    58.8%

    56.5%

    57.9%Exhibit 4MINDRAY MEDICAL INTERNATIONAL LIMITEDRECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION(Dollars in thousands)Three months ended September 30,

    Nine months ended September 30,2009

    2010

    2009

    2010US$

    US$

    US$

    US$(unaudited)

    (unaudited)

    (unaudited)

    (unaudited)GAAP net income

    43,422

    35,938

    101,777

    114,417Interest income

    (1,776)

    (4,157)

    (4,717)

    (8,670)Interest expense

    1,091

    620

    3,881

    2,463Provision for income taxes

    10,209

    6,408

    20,753

    10,118Earnings before interest and taxes ("EBIT")

    52,946

    38,809

    121,694

    118,328Depreciation

    4,720

    4,923

    13,770

    14,139Amortization

    2,392

    2,041

    6,844

    6,302Earnings before interest, taxes, depreciation and amortization ("EBITDA")

    60,058

    45,773

    142,308

    138,769
    '/>"/>

    SOURCE Mindray Medical International Limited
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Mindray Medical Announces Participation in Upcoming Investor Conferences
    2. Mindray to Report Third Quarter 2010 Financial Results on November 8, 2010
    3. Mindray Medical to Exhibit New Products at 64th China International Medical Equipment Fair
    4. Mindray Appoints Mr. Minghe Cheng as Chief Strategic Officer
    5. /C O R R E C T I O N - Mindray Medical International Limited /
    6. Mindray Medical to Present at the Morgan Stanley Global Healthcare Conference
    7. Mindray Medical to Present at the Goldman Sachs 7th Annual European Medtech and Healthcare Services Conference
    8. Mindray Launches New Premium M7 Portable Ultrasound System in U.S.
    9. Mindray to Attend the 2010 American Association for Clinical Chemistry Conference
    10. Mindray to Report Second Quarter 2010 Financial Results on August 9, 2010
    11. Mindray Medical Provides Mid-Year Update on Product Development
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/11/2016)... February 11, 2016 Jeffrey Zucker ... Clinical Trials, will present at this year,s Summit for Clinical ... Regency in Miami, FL. Zucker will ... optimize study execution, supporting SCOPE,s "Improving Site Study Activation and ... on Thursday, Feb. 25 at 11:05 a.m. ...
    (Date:2/11/2016)... 11, 2016 Exactus Pharmacy Solutions, a ... specialty pharmacy care for those suffering from long-term, ... achieved full Specialty Pharmacy Accreditation from URAC, an ... promoting health care quality through accreditation, education and ... The URAC accreditation process demonstrates a commitment ...
    (Date:2/11/2016)... , Feb. 11, 2016 SI-BONE, ... use of the iFuse Implant System, a minimally ... certain disorders of the sacroiliac (SI) joint, announced ... cost benefits of MIS SI joint fusion for ... to degenerative sacroiliitis or SI joint disruption.  In ...
    Breaking Medicine Technology:
    (Date:2/11/2016)... ... 11, 2016 , ... Atlantic Information Services, Inc. (AIS) is ... Case Study for Plans and Purchasers.” Executives from Intel Corp. and Providence Health ... value-based health benefits program Connected Care, will discuss the challenges they faced (and ...
    (Date:2/11/2016)... Australia (PRWEB) , ... February 11, 2016 , ... ... potential ?" motivational speaker, trainer and author Ray Clarke poses a question as ... personal fulfillment . In his book, "Being in the Being" (published by Partridge ...
    (Date:2/11/2016)... ... February 11, 2016 , ... Greenfield ... charity program created to assist the people of their local community. The agency ... organizations and community leaders. Their hope is to bring awareness to important local ...
    (Date:2/11/2016)... ... 2016 , ... Talix today announced that Clive Fields, MD, ... at the 2016 HIMSS Annual Conference & Exhibition, taking place February 29 – ... Coding for Care: Using Data Analytics for Risk Adjustment ,” Dr. Fields will ...
    (Date:2/11/2016)... , ... February 11, 2016 , ... The annual list ... on evaluation of DataPoint’s team dedication and commitment to the SharePoint ecosystem. ... the annual list. The panel’s goal is to recognize and promote technology entrepreneurship. ...
    Breaking Medicine News(10 mins):